who have relapsed within 12 months of their last curative treatment does not improve their survival, results of the
IMpassion132 enrolled 594 patients with unresectable locally advanced or metastatic TNBC who had experienced disease progression more than 12 months after their last treatment for early TNBC with curative intent. The majority had a disease-free interval of less than 6 months after treatment with curative intent. Lung and/orAfter a median follow-up of 9.8 months, overall survival was a median of 12.1 months in the atezolizumab group vs 11.2 months with placebo, at a hazard ratio of 0.93 (A similar result was seen when looking at the modified intention-to-treat population, and when stratifying the patients by prespecified subgroup.
There were no significant differences in progression-free survival or duration of overall response between the atezolizumab and placebo groups. Commenting on the study, Sara M. Tolaney, MD, MPH, chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Boston, questioned the role for immunotherapy in patients with TNBC who experience early relapse.